Haleon plc (LON:HLN) Receives GBX 407.83 Consensus Price Target from Brokerages

Shares of Haleon plc (LON:HLN) have been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is GBX 407.83.

Several equities analysts have commented on HLN shares. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Haleon from GBX 340 to GBX 335 and set a “buy” rating for the company in a research report on Thursday, January 22nd. JPMorgan Chase & Co. boosted their target price on shares of Haleon from GBX 315 to GBX 335 and gave the stock an “underweight” rating in a report on Wednesday, November 26th. Finally, Jefferies Financial Group restated a “buy” rating and set a GBX 450 target price on shares of Haleon in a research report on Wednesday, January 21st.

Haleon Stock Performance

Shares of LON HLN opened at GBX 375 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.93 and a debt-to-equity ratio of 53.60. The stock has a market cap of £33.40 billion, a price-to-earnings ratio of 20.27, a P/E/G ratio of 1.49 and a beta of 0.25. Haleon has a 1-year low of GBX 325.10 and a 1-year high of GBX 419.50. The stock’s 50-day moving average is GBX 384.69 and its 200 day moving average is GBX 366.72.

Haleon (LON:HLN) last posted its earnings results on Thursday, February 26th. The company reported GBX 18.60 earnings per share for the quarter. Haleon had a net margin of 13.81% and a return on equity of 9.40%. On average, sell-side analysts anticipate that Haleon will post 19.5033282 EPS for the current fiscal year.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.